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Background: Latanoprost 0.005% + timolol maleate 0.5% combined eyedrops were recently 
made available in Japan. We prospectively investigated the intraocular pressure (IOP)-lowering 
effect, visual preservation effect, and adverse reactions of a one-year administration of this 
fixed combination.
Methods: The subjects included 162 eyes from 162 patients diagnosed with either primary 
open-angle glaucoma or ocular hypertension and using an unfixed combination of latanoprost 
0.005% and timolol maleate 0.5%. The unfixed combination was discontinued and replaced 
with the latanoprost 0.005% + timolol maleate 0.5% fixed combination with no washout period. 
IOP was measured before (baseline) and 3, 6, 9, and 12 months after the change. The mean 
deviation value of Humphrey field analysis was compared. Adverse reactions were examined 
at every follow-up.
Results: No significant differences were found between mean IOP values obtained at base-
line (mean ± standard deviation, 15.2 ± 3.3 mmHg) 3 months (15.1 ± 3.2 mmHg), 6 months 
(15.3 ± 3.1 mmHg), 9 months (15.3 ± 3.1 mmHg), and 12 months (15.1 ± 3.2 mmHg) after 
the change from the unfixed to the fixed combination of eyedrops (P = 0.212). In addition, 
no significant differences were observed between mean deviation values obtained at baseline 
(−9.11 ± 6.94 dB) and 12 months (−10.08 ± 7.24 dB) after the change (P = 0.114). Thirty-one 
patients discontinued the fixed combination within 12 months of replacement, due to an insuf-
ficient IOP decrease (20 patients, 12.3%) and adverse reactions (11 patients, 6.8%).
Conclusion: Following replacement of two eyedrop medications (latanoprost 0.005% and 
timolol maleate 0.5%) by one fixed combination (latanoprost 0.005% + timolol maleate 0.5%), 
IOP and visual field were preserved. However, 20% of the patients discontinued the new treat-
ment because of an insufficient IOP decrease and complaints of adverse reactions.
Keywords: latanoprost 0.005%, timolol maleate 0.5%, fixed combination, intraocular pressure, 
safety, visual field
Introduction
In recent years, fixed combination eyedrops have been developed to improve adherence 
to glaucoma therapy. In Japan, a fixed combination of eyedrops containing latanoprost 
0.005% + timolol maleate 0.5% (Xalacom® combination eyedrops; Pfizer Japan Inc, 
Japan, Tokyo) has been available on the market since April 2010. In patients who 
were previously receiving latanoprost 0.005% and timolol maleate 0.5% eyedrops 
concomitantly (unfixed combination), changing to the latanoprost 0.005% + timolol 
maleate 0.5% fixed combination resulted in decreased administration frequency and 
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increased adherence. Moreover, this fixed combination is 
expected to decrease intraocular pressure (IOP). However, 
although latanoprost 0.005% + timolol maleate 0.5% fixed 
combination eyedrops are administered once a day, timolol 
maleate 0.5% eyedrops were previously administered twice 
a day, therefore raising concerns about the level of IOP 
decrease provided by the fixed combination. Several studies 
have previously reported shortterm effects on IOP following 
a change to the fixed combination.1−4 In addition, in patients 
with primary open-angle glaucoma and ocular hypertension, 
we described an IOP-lowering effect 3 months after switching 
from the unfixed combination to the latanoprost 0.005% + 
timolol maleate 0.5% fixed combination.5 However, in 
many cases, glaucoma medication is used continuously for 
long periods. Therefore, long-term evaluation of the IOP-
lowering efficacy and safety of latanoprost 0.005% + timolol 
maleate 0.5% fixed combination eyedrops is needed. Further, 
β-blockers are known to show decreased efficacy in reducing 
IOP following long-term administration.6 Nevertheless, the 
reports available concern mostly assessment of effects at 6 
weeks,1 more than 2 months,2 3 months,3,5 and 6 months4 
after changing from the unfixed combination, which are all 
short time periods. There are no reports of long-term admin-
istration. Few reports concern administration of latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrops 
as monotherapy for longer periods of over a year.7−9 Long-
term follow-up of effects on the visual field are also required, 
because this is the final goal of glaucoma treatment. To date, 
only one study has evaluated the effects of the fixed combina-
tion eyedrops on the visual field.9
The present study assessed the long-term effects of 
latanoprost 0.005% + timolol maleate 0.5% fixed combi-
nation eyedrops in patients diagnosed with primary open-
angle glaucoma and ocular hypertension. We prospectively 
investigated the IOP-lowering efficacy and preservation of 
the visual field, as well as safety, after changing from the 
unfixed to the fixed combination for one year. This study 
further extends our previous assessment that had a 3-month 
administration period.5
Materials and methods
Participants were the same as those enrolled in our previ-
ous study.5 We prospectively investigated 162 eyes from 
162 patients (88 men, 74 women) diagnosed at the Inouye 
Eye Hospital from April to October 2010. They were diag-
nosed with either primary open-angle glaucoma (normal 
  tension glaucoma included) or ocular hypertension, and had 
been using latanoprost 0.005% eyedrops and timolol maleate 
0.5% eyedrops concomitantly for more than 3 months. Their 
mean age (± standard deviation) was 64.3 ± 11.4 years, 
ranging from 32 to 87 years. The patient disease types 
included normal tension glaucoma (n = 65), primary open-
angle glaucoma (n = 93), and ocular hypertension (n = 4). 
The criterion for diagnosing normal tension glaucoma was 
IOP # 21 mmHg and for primary open-angle glaucoma was 
IOP . 21 mmHg when measured several times to evaluate 
circadian variation and specific changes of glaucoma in 
the retina nerve fiber layer. The criterion for diagnosing 
ocular hypertension was IOP . 21 mmHg when measured 
several times to evaluate circadian variation and no specific 
changes for glaucoma in the retina nerve fiber layer.   Previous 
treatment with glaucoma eyedrops involved the use of two 
(91 cases), three (58 cases), and four (13 cases) different 
medications. Timolol maleate eyedrops were administered 
as aqueous timolol 0.5% (administered twice a day) in 38 
patients, ion gel-forming timolol 0.5% (administered once 
a day) in 105 patients, or thermogel-forming timolol 0.5% 
(administered once a day) in 19 patients. Patients who had 
undergone glaucoma surgery were excluded. Patients who 
had had cataract surgery within 3 months were also excluded. 
If both eyes met the inclusion criterion, the eye with the 
highest IOP was assessed. If both eyes had the same IOP, 
the right eye was analyzed. In monocular cases, the affected 
eye was subjected to analysis.
The individual latanoprost 0.005% and timolol maleate 
0.5% eyedrops formerly used were discontinued and changed 
to the latanoprost 0.005% + timolol maleate 0.5% fixed 
combination (administered once a day at night) with no 
washout period. Other eyedrop medications were maintained 
as previously. IOP was examined using a Goldmann appla-
nation tonometer. The same investigator performed the IOP 
evaluations before the change from the unfixed to the fixed 
combination and 3, 6, 9, and 12 months after the change, at 
approximately the same time of day. IOP evaluation was 
performed in the total number of cases (n = 162), latano-
prost 0.005% and timolol maleate 0.5% concomitant use 
cases (n = 91), primary open-angle glaucoma cases (n = 93), 
normal tension glaucoma cases (n = 65), and cases in which 
cataract surgery was performed (n = 28) or not performed 
(n = 134). The patients were monitored for adverse reac-
tions at every check-up. The Humphrey 30-2 Sita-Standard 
visual field test program was applied before the change and 
12 months after the change. Patients in whom false-positive 
results, false-negative results, or poor fixation accounted for 
20% or more of the assessments were excluded from evalu-
ation of visual fields. Statistical comparisons of mean IOP 
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values were performed using analysis of variance followed 
by Bonferroni/Dunnett’s tests. Mean deviation values were 
compared using the paired t-test. The significance level was 
set at P , 0.05 for all statistical tests performed. The study 
was reviewed and approved by the institutional review board 
of Inouye Eye Hospital. All participants provided written 
informed consent to participate in the study, and the study 
was conducted in full compliance with the tenets of the 
Declaration of Helsinki.
Results
The mean deviation value before the change (baseline), as 
measured by the Humphrey 30-2 Sita-Standard visual field 
test program, was −9.11 ± 6.94 dB (mean −32.47 ± 1.03 dB). 
The mean IOP at baseline was 15.2 ± 3.3 (8–32) mmHg. 
In the total number of cases (n = 162), no significant dif-
ferences were found between mean IOP values at baseline 
(15.2 ± 3.3 mmHg) and 3 months (15.1 ± 3.2 mmHg), 
6 months (15.3 ± 3.1 mmHg), 9 months (15.3 ± 3.1 mmHg), 
and 12 months (15.1 ± 3.2 mmHg) after the change from the 
unfixed to the fixed combination of eyedrops (P = 0.218, 
Table 1). Six months after the change, IOP decreased by more 
than 2 mmHg in 15 patients (10.6%), increased by more than 
2 mmHg in 27 patients (19.0%), and varied within ±1 mmHg 
in 92 patients (64.8%, Figure 1). Twelve months after the 
change, IOP decreased by more than 2 mmHg in 29 patients 
(21.8%), increased by more than 2 mmHg in 31 patients 
(23.3%), and varied within ±1 mmHg in 66 patients (49.6%). 
No significant differences were found between the mean 
deviation values obtained before (−9.11 ± 6.94 dB) and 
12 months (−10.08 ± 7.24 dB) after the change (P = 0.114, 
Figure 2). On the other hand, in patients using concomitant 
timolol maleate 0.5% and latanoprost 0.005% (n = 91), pri-
mary open-angle glaucoma cases (n = 93), normal tension 
glaucoma cases (n = 65), and cases in which cataract surgery 
was performed (n = 28) or not performed (n = 134), there was 
no disparity in IOP after the change (Table 2).
Thirty-one cases (19.1%) discontinued the new treatment 
within 12 months of starting the fixed combination protocol. 
Reasons for treatment discontinuation included insufficient 
IOP decrease (20 cases, 12.3%) and complaints of adverse 
reactions (11 cases, 6.8%). The following adverse reactions 
were reported by the patients: eye pain (n = 3), itchiness 
(n = 2), stimulation (n = 2), photophobia (n = 1), foreign body 
sensation (n = 1), headache and nausea (n = 1), and dissatis-
faction (n = 1). All adverse reactions disappeared when the 
patients were again administered the individual latanoprost 
0.005% and timolol maleate 0.5% eyedrops.
Discussion
Previous studies1−5 have assessed the short-term effects on 
IOP-lowering efficacy of changing from an unfixed combina-
tion (latanoprost 0.005% and timolol maleate 0.5%) to the 
latanoprost 0.005% + timolol maleate 0.5% fixed combina-
tion eyedrops. Different results were found, ie, no significant 
differences in mean IOP values,3−5 significant decreases,2 and 
significant increases.1
Few reports have assessed the IOP-lowering efficacy 
following long-term administration of the latanoprost 
0.005% + timolol maleate 0.5% fixed combination.7−9 
Rigollet et al randomized 128 patients diagnosed with either 
primary open-angle glaucoma or ocular hypertension into 
three groups.7 Each group received a different formulation 
of fixed combination eyedrops, ie, latanoprost 0.005% + 
timolol maleate 0.5% fixed combination (42 patients), tra-
voprost 0.004% + timolol maleate 0.5% fixed combination 
(44 patients), and bimatoprost 0.03% + timolol maleate 
0.5% fixed combination (42 patients). Mean IOP before 
administration of the latanoprost 0.005% + timolol maleate 
0.5% fixed combination was 27.6 mmHg. However, after 
6 and 12 months of administration of this fixed combina-
tion, mean IOP values significantly decreased and mean 
IOP-lowering values were 8.27 ± 4.56 mmHg and 9.02 ± 
3.63 mmHg, respectively. After 12 months of administra-
tion, the IOP-lowering rate was 32.25%. Adverse reactions 
recorded during the 6-month administration period included 
red eye (23.8%), itching (14.3%), and dryness (14.1%). 
Higginbotham et al also randomized 418 patients diagnosed 
Table 1 Intraocular pressure (IOP) at baseline, 3, 6, 9, and 12 months after the change
Mean IOP ± standard  
deviation (mmHg)
Minimum (mmHg) Maximum (mmHg) P compared with   
IOP at baseline
Baseline 15.2 ± 3.3 8 32 –
3 months after the change 15.0 ± 3.2 8 26 0.218
6 months after the change 15.3 ± 3.1 10 25 0.218
9 months after the change 15.3 ± 3.1 9 24 0.218
12 months after the change 15.1 ± 3.2 8 23 0.218
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with primary open-angle glaucoma, pigmentary glaucoma, 
exfoliation glaucoma, or ocular hypertension into three 
groups, each receiving a different eyedrop formulation for 
6 months, ie, timolol maleate 0.5% eyedrops (140 patients), 
latanoprost 0.005% eyedrops (140 patients), and latanoprost 
0.005% + timolol maleate 0.5% fixed combination eyedrops 
(138 patients).8 At the end of this 6-month period, all patients 
were changed to the latanoprost 0.005% + timolol maleate 
0.5% fixed combination, which was administered for another 
6 months. In patients receiving the latanoprost 0.005% + 
timolol maleate 0.5% fixed combination since the beginning 
of the study, mean IOP values decreased significantly after 
6 (19.4 ± 3.0 mmHg) and 12 (18.9 ± 3.2 mmHg) months of 
administration, compared with the IOP values before admin-
istration (23.1 ± 3.8 mmHg). Schwenn et al p  rospectively 
observed 2339 patients diagnosed with glaucoma or ocular 
hypertension who were previously treated with   monotherapy, 
or unfixed or fixed combinations.9 All patients were 
Increased
more than
2 mmHg,
27 cases,
19.0%
Increased
more than
2 mmHg,
31 cases,
23.3%
Decreased
more than
2 mmHg,
15 cases,
10.6%
6 months after 
the change
12 months after 
the change
Within
1 mmHg,
92 cases,
64.8%
Within
1 mmHg,
66 cases,
49.6%
Decreased
more than
2 mmHg,
29 cases,
21.8%
Figure 1 Frequency of intraocular pressure-lowering at 6 and 12 months after changing from the unfixed combination to the latanoprost 0.005% + timolol maleate 0.5% 
fixed combination eyedrops.
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Figure 2 Mean deviation value obtained before and 12 months after changing from the unfixed combination to the latanoprost 0.005% + timolol maleate 0.5% fixed 
combination eyedrops.
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a  dministered the latanoprost 0.005% + timolol maleate 0.5% 
fixed combination for more than 24 months. In the 1028 
cases in which administration was possible for more than 
24 months, IOP significantly decreased. IOP-lowering values 
recorded at 6, 12, 18, and 24 months were 4.0 ± 4.3 mmHg, 
3.9 ± 4.5 mmHg, 4.0 ± 4.4 mmHg, and 4.2 ± 4.7 mmHg, 
respectively, indicating that IOP-lowering efficacy was 
preserved over 24 months of administration. According to 
these reports7−9 and the results of the present study, possibly 
because timolol maleate is contained in the tested fixed 
combination, IOP-lowering efficacy is maintained throughout 
24 months of administration.
Adverse reactions previously reported for the latanoprost 
0.005% + timolol maleate 0.5% fixed combination include 
hyperemia, stimulation, foreign body sensation, conjuncti-
vitis, and corneal epithelium disorder.1−5,7−9 Most studies, 
including the present one, reported no serious adverse reac-
tions to the fixed combination eyedrops.1−5 Adverse events, 
such as eye pain, itchiness, stimulation, photophobia, foreign 
body sensation, headache, and nausea, reported in the present 
study were almost the same as those reported by previous 
researchers.1–5,7–9 Moreover, the medication was changed 
from concomitant use to a fixed combination in the pres-
ent study. Therefore, new distinctive adverse reactions of 
β-blocker and prostaglandin analogs did not appear and safety 
was satisfactory. In our previous study, an IOP decrease 
of more than 2 mmHg was observed at one (21 patients, 
13.0%) and 3 (29 patients, 20.9%) months after changing to 
the fixed combination.5 Similarly, in the present study, IOP 
decreases .2 mmHg were found at 6 (27 patients, 19.0%) and 
12 (31 patients, 23.3%) months after the change.   However, 
20 patients discontinued the fixed combination within the 
first 12 months of administration because of insufficient 
IOP-lowering efficacy. In addition, some patients exhibited 
IOP increases after changing to the fixed combination. These 
changes are thought to have occurred because timolol maleate 
0.5% was reduced from twice a day to once a day.
In the present study, we also investigated the visual field 
preservation efficacy of the latanoprost 0.005% + timolol 
maleate 0.5% fixed combination. No significant differences 
were found between mean deviation values obtained at base-
line and 12 months after changing to the new   formulation. 
Schwenn et al evaluated changes in the visual field for 
24 months after changing to the latanoprost 0.005% + timolol 
maleate 0.5% fixed combination, using mean defect values 
and the Aulhorn stage classification.9 They found no sig-
nificant differences in mean defect values, when comparing 
data obtained at baseline and 6, 12, 18, and 24 months after 
the change. According to Aulhorn stage, 24 months after 
the change, 59.0% of patients showed no change in visual 
field preservation, 18.9% of patients showed decreased pres-
ervation of the visual field, and 22.1% of patients showed 
an improvement in visual field preservation. Nevertheless, 
progression of visual field disorder is usually very slow. 
Therefore, long-term follow-up is required to document 
better the effects of the fixed combination on preservation 
of the visual field.
The weakness of the present study is that ophthalmoto-
nometry was not masked, the effect of medications other than 
timolol maleate 0.5% and latanoprost 0.005% are assumed, 
and the IOP measurement time was the same in each patient 
but was not standardized in general. Adherence of patients 
was checked at every follow-up visit but does not have 
  reliability. Central corneal thickness was not measured, so 
its influence is not clear. Each factor may have had an influ-
ence on IOP. Therefore, the change in IOP was analyzed in 
Table 2 Intraocular pressure (IOP) at baseline, 3, 6, 9, and 12 months after the change in timolol + latanoprost cases, POAG cases, 
normal tension glaucoma cases, performed cataract surgery cases, and not performed cataract surgery cases
  Baseline 3 months after  
the change
6 months after  
the change
9 months after  
the change 
12 months after  
the change
P compared with   
IOP at baseline
Timolol ± latanoprost  
(91 cases)
14.5 ± 2.7  
(91 cases)
14.5 ± 3.0  
(79 cases)
14.5 ± 2.7  
(76 cases)
14.6 ± 2.7  
(73 cases)
14.5 ± 2.9  
(71 cases)
0.1638
POAG (93 cases) 16.5 ± 3.3  
(93 cases)
16.3 ± 3.2  
(80 cases)
16.3 ± 2.7  
(81 cases)
16.4 ± 2.8  
(79 cases)
16.4 ± 3.4  
(76 cases)
0.0991
Normal tension  
glaucoma (65 cases)
13.1 ± 1.9  
(65 cases)
13.2 ± 2.2  
(56 cases)
13.5 ± 2.7  
(57 cases)
13.5 ± 2.3  
(53 cases)
13.1 ± 2.3  
(52 cases)
0.1794
Cataract surgery            
    Performed  
(28 cases)
16.0 ± 4.7  
(28 cases)
14.6 ± 2.7  
(26 cases)
15.4 ± 3.6  
(26 cases)
15.1 ± 2.9  
(24 cases)
15.1 ± 3.2  
(24 cases)
0.1491
    Not performed  
(134 cases)
15.0 ± 2.9  
(134 cases)
15.1 ± 3.3  
(119 cases)
15.2 ± 2.9  
(110 cases)
15.3 ± 3.1  
(103 cases)
15.1 ± 3.2  
(99 cases)
0.31
Note: Values are presented as mean ± standard deviation (mmHg).
Abbreviations: POAG, primary open-angle glaucoma.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
611
Latanoprost-timolol maleate fixed combinationClinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2012:6
  latanoprost 0.005% and timolol maleate 0.5% fixed combina-
tion cases only, for primary open-angle glaucoma, normal 
tension glaucoma, and in cases where cataract surgery was 
performed and not performed, but there was no change in any 
of the groups. In conclusion, following 12-month replacement 
of two eyedrop medications (latanoprost 0.005% and timolol 
maleate 0.5%) by the latanoprost 0.005% + timolol maleate 
0.5% fixed combination in patients with primary open-angle 
glaucoma or ocular hypertension, IOP was preserved and 
progress of visual field disorder was controlled. However, it 
should be borne in mind that some patients may experience 
adverse reactions, such as eye pain, itchiness, and stimulation, 
or even show increased IOP. Therefore, careful follow-up is 
required after a change to the fixed combination.
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